Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.

Abstract

BACKGROUND:

Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities.

METHODS:

A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%.

RESULTS:

Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis.

CONCLUSIONS:

Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

• Authors: Gautam Borthakur, E Lin, Nitin Jain, Elihu E Estey, Jorge E Cortes, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Sherry Pierce, Hagop Kantarjian
• Journal: Cancer (Cancer) Vol. 115 Issue 14 Pg. 3217-21 (Jul 15 2009) ISSN: 0008-543X [Print] United States
• PMID: 19441109 (Publication Type: Journal Article)

Chemical References

• Core Binding Factors
• Cytarabine

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Core Binding Factors (metabolism)
• Cytarabine (therapeutic use)
• Disease-Free Survival
• Female
• Humans
• Leukemia, Myeloid, Acute (drug therapy, genetics, mortality)
• Male
• Middle Aged
• Neoplasms, Second Primary (mortality)
• Survival Analysis
• Translocation, Genetic